This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Ancrod
Description: Viprinex is derived from the venom of the Malayan pit viper. It is a thrombin-like enzyme that depletes plasma fibrinogen resulting in the disruption of blot clots.
Deal Structure: In March 2002, Empire Pharmaceuticals acquired the exclusive worldwide rights to Viprinex in a royalty-bearing license from Abbott Laboratories. Viprinex was being developed by Knoll AG prior to its acquisition by Abbott in 2001.
In July 2004, upon its acquisition of Empire, Neurobiological Technologies (NTII) acquired the exclusive worldwide rights to Viprinex. Pursuant to the license from Abbott, NTII has an obligation to use commercially reasonable efforts to develop Viprinex for the treatment of ischemic stroke and, if Viprinex receives regulatory approval from the FDA, to market the product for that indication. NTII will be required to make milestone payments of up to an aggregate of $2,000,000. NTII will also be required to make royalty payments to Abbott based on worldwide Viprinex sales. Its royalty obligations will terminate on a country-by-country basis as the applicable patents for Viprinex expire in each applicable country, which will generally occur between 2009 and...See full deal structure in Biomedtracker
Pink Sheet Neurobiological adds VP from Eisai
Additional information available to subscribers only: